Pediatric sublingual allergen immunotherapy.

ABSTRACT

Sublingual immunotherapy (SLIT) offers an important therapeutic modality in the management of children with respiratory allergies. Along with subcutaneous immunotherapy, these modalities are the only selections that have shown not merely relief of symptoms but also disease-modifying activity. SLIT can be given as either a dissolvable tablet (SLIT-T) or liquid drops (SLIT-D). In studies that examined the efficacy and safety in allergic rhinitis and asthma, SLIT-T and SLIT-D both show efficacy in reducing symptoms and the need for medication, although it seems that SLIT-T may show a better response. Almost all SLIT-D efficacy studies are with single allergens. There are virtually no data on the efficacy of mixing unrelated allergens in the same prescription. Both SLIT-T and SLIT-D treatments are safe, with the most common adverse effects being local ones, such as oral pruritus and mouth irritation, which tend to be mild and short lived. Studies that assess the role of SLIT in the prevention of new sensitizations and asthma in the pediatric population are insufficient and of mixed results; therefore, no conclusions can be made. In the treatment of other pediatric conditions, such as food allergy and atopic dermatitis, there are few studies that assessed if, and the degree of, the benefit with SLIT. In determining if SLIT should be prescribed for the pediatric patient, there is a need for shared decision-making to allow the older child and parents or caregivers to understand the pros and cons, and the costs of all the options and relate their values and preferences to the physician.